000170305712-31Q32024falsehttp://www.abcellera.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortizationhttp://www.abcellera.com/20240930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndOtherAccruedLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesabcl:jointVenturexbrli:pureiso4217:CAD00017030572024-01-012024-09-3000017030572024-10-3100017030572023-12-3100017030572024-09-300001703057abcl:ResearchFeesMember2023-07-012023-09-300001703057abcl:ResearchFeesMember2024-07-012024-09-300001703057abcl:ResearchFeesMember2023-01-012023-09-300001703057abcl:ResearchFeesMember2024-01-012024-09-300001703057us-gaap:LicenseMember2023-07-012023-09-300001703057us-gaap:LicenseMember2024-07-012024-09-300001703057us-gaap:LicenseMember2023-01-012023-09-300001703057us-gaap:LicenseMember2024-01-012024-09-300001703057abcl:MilestonePaymentsMember2023-07-012023-09-300001703057abcl:MilestonePaymentsMember2024-07-012024-09-300001703057abcl:MilestonePaymentsMember2023-01-012023-09-300001703057abcl:MilestonePaymentsMember2024-01-012024-09-3000017030572023-07-012023-09-3000017030572024-07-012024-09-3000017030572023-01-012023-09-300001703057us-gaap:CommonStockMember2023-12-310001703057us-gaap:AdditionalPaidInCapitalMember2023-12-310001703057us-gaap:RetainedEarningsMember2023-12-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001703057us-gaap:CommonStockMember2024-01-012024-03-310001703057us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100017030572024-01-012024-03-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001703057us-gaap:RetainedEarningsMember2024-01-012024-03-310001703057us-gaap:CommonStockMember2024-03-310001703057us-gaap:AdditionalPaidInCapitalMember2024-03-310001703057us-gaap:RetainedEarningsMember2024-03-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100017030572024-03-310001703057us-gaap:CommonStockMember2024-04-012024-06-300001703057us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000017030572024-04-012024-06-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001703057us-gaap:RetainedEarningsMember2024-04-012024-06-300001703057us-gaap:CommonStockMember2024-06-300001703057us-gaap:AdditionalPaidInCapitalMember2024-06-300001703057us-gaap:RetainedEarningsMember2024-06-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000017030572024-06-300001703057us-gaap:CommonStockMember2024-07-012024-09-300001703057us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001703057us-gaap:RetainedEarningsMember2024-07-012024-09-300001703057us-gaap:CommonStockMember2024-09-300001703057us-gaap:AdditionalPaidInCapitalMember2024-09-300001703057us-gaap:RetainedEarningsMember2024-09-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001703057us-gaap:CommonStockMember2022-12-310001703057us-gaap:AdditionalPaidInCapitalMember2022-12-310001703057us-gaap:RetainedEarningsMember2022-12-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100017030572022-12-310001703057us-gaap:CommonStockMember2023-01-012023-03-310001703057us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100017030572023-01-012023-03-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001703057us-gaap:RetainedEarningsMember2023-01-012023-03-310001703057us-gaap:CommonStockMember2023-03-310001703057us-gaap:AdditionalPaidInCapitalMember2023-03-310001703057us-gaap:RetainedEarningsMember2023-03-310001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100017030572023-03-310001703057us-gaap:CommonStockMember2023-04-012023-06-300001703057us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000017030572023-04-012023-06-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001703057us-gaap:RetainedEarningsMember2023-04-012023-06-300001703057us-gaap:CommonStockMember2023-06-300001703057us-gaap:AdditionalPaidInCapitalMember2023-06-300001703057us-gaap:RetainedEarningsMember2023-06-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000017030572023-06-300001703057us-gaap:CommonStockMember2023-07-012023-09-300001703057us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001703057us-gaap:RetainedEarningsMember2023-07-012023-09-300001703057us-gaap:CommonStockMember2023-09-300001703057us-gaap:AdditionalPaidInCapitalMember2023-09-300001703057us-gaap:RetainedEarningsMember2023-09-300001703057us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000017030572023-09-300001703057us-gaap:ComputerEquipmentMember2023-12-310001703057us-gaap:ComputerEquipmentMember2024-09-300001703057us-gaap:LandMember2023-12-310001703057us-gaap:LandMember2024-09-300001703057us-gaap:BuildingMember2023-12-310001703057us-gaap:BuildingMember2024-09-300001703057abcl:LaboratoryEquipmentMember2023-12-310001703057abcl:LaboratoryEquipmentMember2024-09-300001703057us-gaap:LeaseholdImprovementsMember2023-12-310001703057us-gaap:LeaseholdImprovementsMember2024-09-300001703057abcl:LeaseholdImprovementsAndConstructionInProgressMember2023-12-310001703057abcl:LeaseholdImprovementsAndConstructionInProgressMember2024-09-300001703057abcl:ConstructionDepositsMember2023-12-310001703057abcl:ConstructionDepositsMember2024-09-300001703057abcl:LicenseBasedIntangibleAssetsMember2023-12-310001703057abcl:LicenseBasedIntangibleAssetsMember2024-09-300001703057us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001703057us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300001703057us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001703057us-gaap:InProcessResearchAndDevelopmentMember2024-09-300001703057abcl:BeedieJointVentureMember2024-09-300001703057abcl:DayhuJointVentureMember2024-09-300001703057abcl:DayhuJointVentureMember2023-12-310001703057abcl:DayhuJointVentureMember2023-07-012023-09-300001703057abcl:DayhuJointVentureMember2023-01-012023-09-300001703057abcl:DayhuJointVentureMember2024-07-012024-09-300001703057abcl:DayhuJointVentureMember2024-01-012024-09-300001703057abcl:DayhuJointVentureMemberabcl:DayluJVLoanMember2023-12-310001703057abcl:DayhuJointVentureMemberabcl:DayluJVLoanMember2024-09-300001703057abcl:BeedieJointVentureMember2023-12-310001703057abcl:BeedieJointVentureMembersrt:MaximumMember2023-12-310001703057abcl:BeedieJointVentureMembersrt:MaximumMember2024-09-300001703057abcl:PreInitialPublicOfferingPlanMember2023-12-310001703057abcl:PreInitialPublicOfferingPlanMember2024-01-012024-09-300001703057abcl:PreInitialPublicOfferingPlanMember2024-09-300001703057abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2023-12-310001703057abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2024-01-012024-09-300001703057abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2024-09-300001703057us-gaap:RestrictedStockUnitsRSUMemberabcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2023-12-310001703057us-gaap:RestrictedStockUnitsRSUMemberabcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2024-01-012024-09-300001703057us-gaap:RestrictedStockUnitsRSUMemberabcl:TwoThousandTwentyShareOptionAndIncentivePlanMember2024-09-300001703057us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001703057us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001703057us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001703057us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001703057us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001703057us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001703057us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001703057us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001703057us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001703057us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001703057us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001703057us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001703057abcl:TrianniMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-06-300001703057abcl:TrianniMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-07-012024-09-300001703057abcl:TrianniMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-09-300001703057abcl:TetraGeneticMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-06-300001703057abcl:TetraGeneticMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-07-012024-09-300001703057abcl:TetraGeneticMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-09-300001703057abcl:TrianniMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2023-12-310001703057abcl:TrianniMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-01-012024-09-300001703057abcl:TetraGeneticMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2023-12-310001703057abcl:TetraGeneticMemberus-gaap:FairValueInputsLevel3Memberabcl:ContingentConsiderationMember2024-01-012024-09-300001703057abcl:TrianniMemberus-gaap:MeasurementInputDiscountRateMember2024-09-300001703057abcl:TetraGeneticMemberus-gaap:MeasurementInputDiscountRateMember2024-09-300001703057abcl:TetraGeneticMember2024-01-012024-06-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001703057us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001703057us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001703057us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001703057us-gaap:FairValueMeasurementsRecurringMember2024-09-300001703057abcl:TransactionOneMember2020-05-310001703057abcl:TransactionOneMember2024-01-012024-09-300001703057country:CAabcl:NonRepayableMemberabcl:TransactionOneMember2024-01-012024-09-300001703057country:CAabcl:ConditionallyRepayableMemberabcl:TransactionOneMember2024-01-012024-09-300001703057abcl:TransactionOneMember2024-09-300001703057abcl:TransactionTwoMember2023-05-310001703057country:CAabcl:TransactionTwoMember2023-05-310001703057country:CAabcl:NonRepayableMemberabcl:TransactionTwoMember2023-05-310001703057country:CAabcl:RepayableMemberabcl:TransactionTwoMember2023-05-310001703057country:CAabcl:ConditionallyRepayableMemberabcl:TransactionTwoMember2023-05-310001703057country:CAabcl:TransactionTwoMember2023-05-012023-05-310001703057country:CAabcl:TransactionTwoMember2023-05-012024-09-300001703057stpr:CA-BCabcl:TransactionTwoMember2024-09-300001703057stpr:CA-BCabcl:TransactionTwoMember2024-01-012024-09-300001703057stpr:CA-BCabcl:ConditionallyRepayableMemberabcl:TransactionTwoMember2024-09-300001703057stpr:CA-BCabcl:ConditionallyRepayableMemberabcl:TransactionTwoMember2024-01-012024-09-300001703057stpr:CA-BCabcl:TransactionTwoMember2023-05-012024-09-300001703057country:CAabcl:TransactionOneMember2024-09-300001703057country:CAabcl:NonRepayableMemberabcl:TransactionOneMember2024-09-300001703057country:CAabcl:ConditionallyRepayableMemberabcl:TransactionOneMember2024-09-300001703057country:CAabcl:RepayableMemberabcl:TransactionOneMember2024-09-300001703057country:CAabcl:TransactionTwoMember2024-09-300001703057country:CAabcl:NonRepayableMemberabcl:TransactionTwoMember2024-09-300001703057country:CAabcl:ConditionallyRepayableMemberabcl:TransactionTwoMember2024-09-300001703057country:CAabcl:RepayableMemberabcl:TransactionTwoMember2024-09-300001703057stpr:CA-BCabcl:NonRepayableMemberabcl:TransactionTwoMember2024-09-300001703057stpr:CA-BCabcl:RepayableMemberabcl:TransactionTwoMember2024-09-300001703057abcl:OtherGovernmentGrantsMember2024-09-300001703057abcl:NonRepayableMemberabcl:OtherGovernmentGrantsMember2024-09-300001703057abcl:ConditionallyRepayableMemberabcl:OtherGovernmentGrantsMember2024-09-300001703057abcl:RepayableMemberabcl:OtherGovernmentGrantsMember2024-09-300001703057abcl:NonRepayableMember2024-09-300001703057abcl:ConditionallyRepayableMember2024-09-300001703057abcl:RepayableMember2024-09-300001703057abcl:NonRepayableMember2023-12-310001703057abcl:ConditionallyRepayableMember2023-12-310001703057abcl:RepayableMember2023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________________________________________________
FORM 10-Q
_________________________________________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 001-39781
_________________________________________________________
AbCellera Biologics Inc.
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________
British ColumbiaNot Applicable
( State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
2215 Yukon Street
Vancouver, BC
V5Y 0A1
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (604) 559-9005
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common shares, no par value per shareABCLThe Nasdaq Stock Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 31, 2024, the registrant had 295,366,280 common shares, no par value per share, outstanding.


Table of Contents
i

Summary of the Material and Other Risks Associated with Our Business
Our business is subject to numerous material and other risks and uncertainties. You should carefully consider the following information together with the other information appearing elsewhere in this Quarterly Report, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material, may impair our business. These risks include, but are not limited to, the following:
•We have incurred losses in certain years since inception, including in 2023 and 2024, and we may not be able to generate sufficient revenue to achieve profitability.
•Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
•Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and share price.
•Our commercial success depends on the quality of our antibody discovery and development engine and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry.
•Failure to execute our business strategy could adversely impact our growth and profitability.
•If we cannot maintain and expand current partnerships and enter new partnerships that generate discovery programs for antibodies, our business could be adversely affected.
•Development of a biological molecule is inherently uncertain, and it is possible that none of the antibody drug candidates discovered using our antibody discovery and development engine that are further developed by us or our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.
•The failure of our partners to meet their contractual obligations to us could adversely affect our business.
•We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy.
•We have invested, and expect to continue to invest, in research and development efforts that further enhance our technology and platform. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.
•Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs with the antibodies that we have discovered, and the price of our common shares may decline as a result of announcements of unexpected results or developments.
•Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common shares to decline.
•We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
•The life sciences and biotechnology platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve profitability.
•Upgrading and integrating our business systems could result in implementation issues and business disruptions.
•If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including our discovery and development engine, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our data packages may be impaired.
•If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.
ii

•Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse non-cash accounting impact on our results of operations.
•Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well.
Investing in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties contained in Part II, Item 1A, Risk Factors, together with all other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our other filings with the Securities and Exchange Commission, or the SEC, before investing in our common shares. Any of the risk factors we describe below under Part II, Item 1A, Risk Factors, could adversely affect our business, financial condition or results of operations. The market price of our common shares could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common shares. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See “Forward-Looking Information” in this Quarterly Report on Form 10-Q.
iii

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
AbCellera Biologics Inc.
Condensed Consolidated Balance Sheets
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)
December 31, 2023September 30, 2024
Assets
Current assets:
Cash and cash equivalents$133,320 $126,640 
Marketable securities627,265 516,499 
Total cash, cash equivalents, and marketable securities760,585 643,139 
Accounts and accrued receivable30,590 31,373 
Restricted cash25,000 25,000 
Other current assets55,810 43,371 
Total current assets871,985 742,883 
Long-term assets:
Property and equipment, net287,696 331,263 
Intangible assets, net120,425 52,577 
Goodwill47,806 47,806 
Investments in equity accounted investees65,938 84,084 
Other long-term assets94,244 134,215 
Total long-term assets616,109 649,945 
Total assets$1,488,094 $1,392,828 
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other current liabilities$49,580 $53,773 
Contingent consideration payable50,475 20,217 
Deferred revenue18,958 5,578 
Total current liabilities119,013 79,568 
Long-term liabilities:
Operating lease liability71,222 66,274 
Deferred revenue8,195 8,100 
Deferred government contributions95,915 142,046 
Contingent consideration payable4,913 4,441 
Deferred tax liability30,612 12,781 
Other long-term liabilities5,906 1,524 
Total long-term liabilities216,763 235,166 
Total liabilities335,776 314,734 
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2023 and September 30, 2024: 290,824,970 and 295,157,474 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively
753,199 772,832 
Additional paid-in capital121,052 155,354 
Accumulated other comprehensive loss(1,720)(1,232)
Accumulated earnings279,787 151,140 
Total shareholders' equity1,152,318 1,078,094 
Total liabilities and shareholders' equity$1,488,094 $1,392,828 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AbCellera Biologics Inc.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
(Unaudited)
Three months ended September 30,Nine months ended September 30,
2023202420232024
Revenue:
Research fees$6,413 $6,289 $26,812 $21,516 
Licensing revenue186 218 784 767 
Milestone payments– – 1,250 1,500 
Total revenue6,599 6,507 28,846 23,783 
Operating expenses:
Research and development(1)
37,917 40,969 127,036 121,183 
Sales and marketing(1)
3,468 3,135 11,080 9,635 
General and administrative(1)
14,369 19,147 45,025 56,691 
Depreciation, amortization, and impairment5,735 36,919 16,859 78,285 
Total operating expenses61,489 100,170 200,000 265,794 
Loss from operations(54,890)(93,663)(171,154)(242,011)
Other income:
Interest income(10,740)(9,603)(31,278)(29,805)
Grants and incentives(2,828)(3,491)(10,779)(10,076)
Other income (2,046)(17,937)(3,670)(48,564)
Total other income(15,614)(31,031)(45,727)(88,445)
Net loss before income tax(39,276)(62,632)(125,427)(153,566)
Income tax recovery(10,666)(11,525)(26,179)(24,919)
Net loss$(28,610)$(51,107)$(99,248)$(128,647)
Foreign currency translation adjustment439 841 (69)488 
Comprehensive loss$(28,171)$(50,266)$(99,317)$(128,159)
Net loss per share
Basic$(0.10)$(0.17)$(0.34)$(0.44)
Diluted$(0.10)$(0.17)$(0.34)$(0.44)
Weighted-average common shares outstanding
Basic289,496,841294,851,945288,750,387293,930,702
Diluted289,496,841294,851,945288,750,387293,930,702
The accompanying notes are an integral part of these condensed consolidated financial statements.
1Exclusive of depreciation, amortization, and impairment
2

AbCellera Biologics Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)

Common SharesAdditional
Paid-in
Capital		Accumulated
Earnings		Accumulated
Other
Comprehensive
Loss		Total
Shareholders'
Equity
SharesAmount
Balances as of December 31, 2023290,824,970$753,199 $121,052 $279,787 $(1,720)$1,152,318 
Shares issued and restricted stock units ("RSUs") vested under stock option plan2,796,34211,363(10,471)––892
Stock-based compensation expense––17,409––17,409
Foreign currency translation adjustment––––(96)(96)
Net loss–––(40,610)–(40,610)
Balances as of March 31, 2024293,621,312$764,562 $127,990 $239,177 $(1,816)$1,129,913 
Shares issued and restricted stock units ("RSUs") vested under stock option plan1,044,2205,404(4,944)––460
Stock-based compensation expense––17,782––17,782
Foreign currency translation adjustment––––(257)(257)
Net loss–––(36,930)–(36,930)
Balances as of June 30, 2024294,665,532$769,966 $140,828 $202,247 $(2,073)$1,110,968 
Shares issued and restricted stock units ("RSUs") vested under stock option plan491,9422,866(2,638)––228
Stock-based compensation expense––17,164––17,164
Foreign currency translation adjustment––––841841
Net loss–––(51,107)–(51,107)
Balances as of September 30, 2024295,157,474$772,832 $155,354 $151,140 $(1,232)$1,078,094 
Common SharesAdditional
Paid-in
Capital		Accumulated
Earnings		Accumulated
Other
Comprehensive
Loss		Total
Shareholders'
Equity
SharesAmount
Balances as of December 31, 2022286,851,595$734,365 $74,118 $426,185 $(1,391)$1,233,277 
Shares issued and restricted stock units ("RSUs") vested under stock option plan 1,574,9198,451(7,962)– – 489
Share-based compensation expense– – 15,474– – 15,474
Foreign currency translation adjustment– – – – (630)(630)
Net loss– – – (40,110)– (40,110)
Balances as of March 31, 2023288,426,514$742,816 $81,630 $386,075 $(2,021)$1,208,500 
Shares issued and restricted stock units ("RSUs") vested under stock option plan762,9551,940 (1,606)– – 334 
Share-based compensation expense– – 16,399 – – 16,399 
Foreign currency translation adjustment– – – – 122 122 
Net loss– – – (30,528)– (30,528)
Balances as of June 30, 2023289,189,469$744,756 $96,423 $355,547 $(1,899)$1,194,827 
Shares issued and restricted stock units ("RSUs") vested under stock option plan588,1853,158 (2,901)– – 257 
Share-based compensation expense– – 15,862 – – 15,862 
Foreign currency translation adjustment– – – – 439 439 
Net loss– – – (28,610)– (28,610)
Balances as of September 30, 2023289,777,654$747,914 $109,384 $326,937 $(1,460)$1,182,775 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AbCellera Biologics Inc.
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars.)
(Unaudited)
Nine months ended September 30,
20232024
Cash flows from operating activities:
Net loss$(99,248)$(128,647)
Cash flows from operating activities:
Depreciation of property and equipment8,874 10,437 
Amortization and impairment of intangible assets7,985 67,848 
Amortization of operating lease right-of-use assets4,926 4,813 
Stock-based compensation47,735 52,355 
Fair value gain on contingent consideration and investments– (48,727)
Deferred income tax and other(6,354)(17,891)
Changes in operating assets and liabilities:
Research fees and grants receivable(35,495)(54,258)
Accrued royalties receivable9,273 – 
Income taxes payable (receivable)28,685 (8,709)
Accounts payable and accrued liabilities(1,852)4,018 
Deferred revenue(7,238)(13,474)
Accrued royalties payable(16,253)– 
Deferred grant income30,377 30,671 
Other assets4,319 1,008 
Net cash used in operating activities(24,266)(100,556)
Cash flows from investing activities:
Purchases of property and equipment(62,516)(62,766)
Purchase of marketable securities(744,674)(612,249)
Proceeds from marketable securities642,913 735,989 
Receipt of grant funding15,023 29,150 
Long-term investments and other assets(37,317)13,538 
Investment in equity accounted investees(10,214)(17,956)
Net cash provided by (used in) investing activities(196,785)85,706 
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other(1,049)(552)
Proceeds from long-term liabilities6,560 7,599 
Proceeds from exercise of stock options1,080 1,580 
Net cash provided by financing activities6,591 8,627 
Effect of exchange rate changes on cash and cash equivalents(479)(457)
Decrease in cash and cash equivalents(214,939)(6,680)
Cash and cash equivalents and restricted cash, beginning of period414,651 160,610 
Cash and cash equivalents and restricted cash, end of period$199,712 $153,930 
Restricted cash included in other assets2,290 2,290 
Total cash, cash equivalents, and restricted cash shown on the balance sheet$197,422 $151,640 
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable12,948 15,989 
Right-of-use assets obtained in exchange for operating lease obligation3,586 2,232 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

AbCellera Biologics Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)
1. Nature of operations
AbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.
2. Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2023.
These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2023 and 2024 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2023.
All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.
3. Significant accounting policies
Use of estimates
The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
Recent accounting pronouncements not yet adopted
The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.
5

4. Net loss per share
Basic and diluted net loss per share was calculated as follows:
Three months ended September 30,Nine months ended September 30,
Basic and diluted loss per share2023202420232024
Net loss$(28,610)$(51,107)$(99,248)$(128,647)
Weighted-average common shares outstanding289,496,841294,851,945288,750,387293,930,702
Net loss per share - basic and diluted$(0.10)$(0.17)$(0.34)$(0.44)
The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2023 and September 30, 2024 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three and nine months ended September 30, 2023 and September 30, 2024 used to calculate both basic and diluted net loss per share is the same.
The Company excluded 50,081,069 and 50,544,294 potential common shares for the three and nine months ended September 30, 2023, and 58,027,706 and 58,543,314 potential common shares for the three and nine months ended September 30, 2024, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.
5. Property and equipment, net
Property and equipment, net consisted of the following:
December 31, 2023September 30, 2024
Computers$3,517 $5,365 
Land53,405 53,405 
Building43,947 66,919 
Laboratory equipment70,350 79,486 
Leasehold improvements73,944 96,487 
Operating lease right-of-use assets73,141 68,319 
Property and equipment318,304 369,981 
Less: accumulated depreciation(30,608)(38,718)
Property and equipment, net$287,696 $331,263 
As of December 31, 2023 and September 30, 2024, property and equipment includes leasehold improvements and construction in progress in the amount of $91.0 million and $93.0 million, respectively, and construction deposits of $13.7 million and $15.4 million, respectively, that have not commenced depreciation. Depreciation expense on property and equipment for the three and nine months ended September 30, 2023 was $3.1 million and $8.9 million, respectively, and $3.8 million and $10.4 million for the three and nine months ended September 30, 2024, respectively.
6. Intangible assets
Intangible assets consisted of the following:

6

December 31, 2023September 30, 2024
Gross
carrying
amount		Accumulated
amortization		Net book
value		Gross
carrying
amount		Accumulated
amortization		Net book
value
License38,433 26,861 11,572 38,433 28,723 9,710 
Technology52,700 7,857 44,843 52,700 9,833 42,867 
IPR&D64,010 – 64,010 — – – 
155,143 34,718 120,425 91,133 38,556 52,577 
For the quarter ended September 30, 2024, the Company recorded a full impairment charge of the carrying value of $32.0 million (or $23.3 million, net of deferred income tax) associated with the IPR&D acquired through the 2020 acquisition of Trianni. The impairment was due to our ongoing internal program prioritization which resulted in the discontinuance of the development of the next-generation transgenic mice.
In the quarter ended June 30, 2024, the Company recorded a full impairment charge of the carrying value of $32.0 million (or $23.7 million, net of deferred income tax) associated with the IPR&D acquired through the 2021 acquisition of TetraGenetics. The impairment was a result of the Company's ongoing internal program prioritization. Details of a corresponding impact to contingent consideration associated with the TetraGenetics acquisition are disclosed in Note 11.
The impairments are reflected within Depreciation, amortization, and impairment expense.
Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended September 30:
Amortization
Expense
2025$4,297 
20264,297 
20274,297 
20284,297 
20294,297 
$21,485 
7. Investments in equity accounted investees, and other long-term assets
The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of future office and laboratory headquarters. The Company recorded immaterial amounts of proportionate income or loss with respect to either venture in the three and nine months ended September 30, 2023 and 2024.

Dayhu JV
As of December 31, 2023 and September 30, 2024, the equity investment balance was $42.1 million and $42.8 million, respectively. Substantially all the assets in the Dayhu JV are comprised of property and equipment. As of December 31, 2023 and September 30, 2024, the Company recorded a right-of-use asset of $49.1 million and $49.5 million, respectively, and an operating lease liability of $50.4 million and $50.1 million, respectively, associated with an office lease with the Dayhu JV. In the three and nine months ended September 30, 2023, the Company incurred lease expense of $1.3 million and $4.0 million, respectively, and $1.3 million and $4.0 million in the three and nine months ended September 30, 2024, respectively, to the Dayhu JV included within operating expenses.
At December 31, 2023 and September 30, 2024, the Company had a loan receivable balance of CAD $45.9 million ($34.7 million) and CAD $46.3 million ($34.0 million), respectively, directly with our JV partner, Dayhu, included in other long-term assets.
7

Beedie JV
As of December 31, 2023 and September 30, 2024, the equity investment balance was $23.8 million and $41.2 million, respectively, of which substantially all the assets in the Beedie JV is comprised of property and equipment.
At December 31, 2023 and September 30, 2024, the Company had a loan receivable balance of CAD $18.4 million ($13.9 million) and CAD $40.4 million ($29.9 million), respectively, directly with our JV partner, Beedie, which relates to the land and construction loan and is included in other long-term assets.
8. Other current assets and liabilities
Other current assets
December 31, 2023September 30, 2024
Taxes receivable$33,792 $31,863 
Prepaid expenses and other22,018 11,508 
Total other current assets$55,810 $43,371 

Current accounts payable and other current liabilities
December 31, 2023September 30, 2024
Accounts payable and accrued liabilities$28,603 $34,795 
Current portion of operating lease liability6,158 5,125 
Payroll liabilities7,707 5,992 
Current portion of deferred government contribution7,112 7,861 
Total accounts payable and other current liabilities$49,580 $53,773 
9. Shareholders’ equity
The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2023:
Number of
Shares		Weighted-
Average Exercise
Price 
Outstanding as of December 31, 202330,647,575$0.94 
Granted––
Exercised(3,380,807)0.49 
Forfeited(3,750)1.22
Outstanding as of September 30, 202427,263,018$0.99 
Options exercisable as of September 30, 202425,985,445$0.95 
8

The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2023:
Number of
Shares		Weighted-
Average Exercise
Price
Outstanding as of December 31, 202313,992,304$13.82 
Granted10,829,5895.22 
Exercised––
Forfeited(905,020)11.80 
Outstanding as of September 30, 202423,916,873$10.00 
Options exercisable as of September 30, 20247,799,362$15.12 
The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2023:
Number of
Shares		Weighted-
Average Grant
Date Fair Value
Outstanding as of December 31, 20234,075,590$11.61 
Granted4,080,0535.28 
Vested and settled(951,697)12.69 
Forfeited(356,131)8.57 
Outstanding as of September 30, 20246,847,815$7.85 
As of September 30, 2024, the number of shares available for issuance under the 2020 Plan was 33,842,104, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.
Stock-based compensation:
Stock-based compensation expense was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
Three months ended September 30,Nine months ended September 30,
2023202420232024
Research and development$7,796 $7,621 $23,370 $24,199 
Sales and marketing1,264 1,545 3,864 4,473 
General and administrative6,802 7,998 20,501 23,683 
$15,862 $17,164 $47,735 $52,355 
10. Revenue
The disaggregated revenue categories are presented on the face of the condensed consolidated statements of loss and comprehensive loss. Deferred revenue outstanding in each respective period is as follows:
December 31, 2022September 30, 2023December 31, 2023September 30, 2024
Deferred revenue$41,128 $33,890 $27,153 $13,678 
During the three and nine months ended September 30, 2023, the Company recognized $4.1 million and $11.0 million, respectively, and $5.9 million and $18.9 million, respectively, in the three and nine months ended September 30, 2024, of revenue that had been included in deferred revenue as of December 31, 2022 and December 31, 2023.
9

11. Financial instruments
Fair Value Measurements
The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.
The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, accounts payable and other liabilities, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and other liabilities, and loans receivable approximate their fair values, and are primarily classified as Level 2.
At September 30, 2024, the Company also held non-marketable securities included in other long term assets of $32.3 million (December 31, 2023 - $32.3 million). These non-marketable securities are measured at cost less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. In the quarter ended September 30, 2024, one of the Company's non-marketable securities was disposed of, resulting in a recognized gain of $16.5 million reflected within other income.
Contingent Consideration
Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition.
The following table presents the changes in fair value of the liability for contingent consideration:
Three Months Ended September 30, 2024Liability at
beginning of
the period		Increase in fair
value of liability for contingent
consideration		Liability at
end of the
period
Trianni (i)$20,027 $190 $20,217 
TetraGenetics (ii)$4,441 $– $4,441 
Nine Months Ended September 30, 2024Liability at
beginning of
the period		Increase (decrease) in fair
value of liability for contingent
consideration		Liability at
end of the
period
Trianni (i)$18,697 $1,520 $20,217 
TetraGenetics (ii)$36,691 $(32,250)$4,441 
i)The estimated fair value of the earn-out payments relates to a specific customer license and the fair value was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions inherent in the development of the value include the amount and timing of projected future net revenues received by us from the specific customer license, and the discount rate selected to measure the risks inherent in the future cash flows, which was approximately 22.0%.
ii)The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 12.8%, the rate that measures the risks inherent in the future cash flows. In the quarter ended June 30, 2024, the fair value of the contingent consideration was adjusted to reflect the expected value of the Company's ongoing internal program prioritization, resulting in a reduction of $32.4 million recognized as a non-cash fair value gain through other income.
10

In-Process Research and Development Assets
As discussed in Note 6, the estimated fair values in support of the TetraGenetics full impairment charge were categorized within Level 3 of the fair value hierarchy and were determined using an income-based approach, which was based on a probability-adjusted present value of the future estimated after-tax cash flows attributable to the intangible assets. The significant assumptions inherent in estimating the fair values, from the perspective of a market participant, include a probability-adjusted success rate of its continued development through to clinical trials, future revenue, operating and development costs, milestone and regulatory success, obsolescence, and profitability. A de-risked discount rate of 12.8% for TetraGenetics was used to present value the probability of success risk adjusted after-tax cash flows attributable to the IPR&D.
Marketable Securities
As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations. As of September 30, 2024, our marketable securities were rated A- or higher (or its equivalent) by at least two of the major rating agencies with a weighted average life of approximately 0.5 years.
Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.
The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
Fair Value Measurements at September 30, 2024:
Level 1Level 2Level 3Total
Marketable securities
U.S. government agencies$113,838 $– $– $113,838 
Certificate of deposit– 120,297 – 120,297 
Commercial paper– 48,484 – 48,484 
Corporate bonds– 128,973 – 128,973 
Asset backed securities– 104,907 – 104,907 
$113,838 $402,661 $– $516,499 
12. Commitments and contingencies
From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.
The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.
Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. No amounts were expensed during the three and nine months ended September 30, 2023 or September 30, 2024.
13. Government contributions
Government Contribution 1
11

In May of 2020, the Company received a funding commitment from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) for a total of CAD $175.6 million ($125.6 million), collectively "Government Contribution 1" which is intended to support research and development efforts related to the discovery of antibodies to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapeutics against future pandemic threats. From inception to September 30, 2024, the Company incurred CAD $169.4 million ($130.2 million) in expenditures in respect of the Canadian government's Strategic Innovation Fund (SIF), of which CAD $58.7 million ($46.1 million) and CAD $110.7 million ($84.1 million) relate to phase 1 and 2, respectively as defined in the agreement. Spending under phase 1 of the agreement and such amounts are non-repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of September 30, 2024, no amounts have been accrued related to the repayment terms.
Government Contribution 2
In May of 2023, the Company entered into multi-year contribution agreements with the Government of Canada and the Government of British Columbia for a total of CAD $300.0 million ($222.3 million), collectively "Government Contribution 2." These investments are intended to build new capabilities in Canada to develop, manufacture, and deliver antibody medicines to patients through Phase 1 clinical trials and build expertise in translational science, technical operations, and clinical operations and research.
The Government of Canada has committed up to CAD $225.0 million ($166.7 million) of which CAD $56.2 million ($41.6 million) is non-repayable, CAD $78.8 million ($58.4 million) is repayable and CAD $90.0 million ($66.7 million) is conditionally repayable. Both the repayable and conditionally repayable amounts are repayable starting in 2033. The repayable funding is payable over fifteen years and the conditionally repayable portion repaid is based on a computed percentage rate of the Company’s revenue over a period of up to fifteen years, at a factor of up to 1.4 times the original conditionally repayable grant. The agreement will expire on the later of April 30, 2047, or the date of the last repayment, unless earlier terminated. From inception to September 30, 2024, the Company has recorded CAD $57.2 million ($42.4 million) in respect of the funding.
The Government of British Columbia has committed up to CAD $75.0 million ($55.6 million) which includes partial reimbursement of certain eligible expenditures up to CAD $37.5 million ($27.8 million) towards eligible infrastructure investments paid over five years; and a CAD $37.5 million ($27.8 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia. Up to a maximum of CAD $64.0 million ($48.0 million) may become payable starting in 2032, over up to fifteen years, conditional to the Company achieving revenue exceeding a given threshold. The agreement will expire on the earlier of 2047, or the date of the last payment, unless earlier terminated, as prescribed in the agreement. From inception to September 30, 2024, the Company has recorded CAD $37.2 million ($27.6 million) in respect of the funding commitment.

Impact to Consolidated Financial Statements
The Company recognized the following on the consolidated balance sheets:
September 30, 2024
Deferred Government Contribution
Accounts Receivable
Government Grant1
Total
Non-repayable
Conditionally Repayable2
Repayable
Government Contribution 1 (Canada)$13,378 $6,558 $76,046 $– $82,604 
Government Contribution 2 (Canada)16,176 6,735 – 32,629 39,364 
Government Contribution 2 (British Columbia)22,575 – 26,952 – 26,952 
Other Government Grants– 987 – – 987 
September 30, 2024$52,129 $14,280 $102,998 $32,629 $149,907 
December 31, 2023$36,051 $14,811 $71,796 $16,420 $103,027 
September 30, 2024
Current$27,053 $4,351 $3,510 $– $7,861 
Long-term$25,076 $9,929 $99,488 $32,629 $142,046 
1 Government Contributions are amortized into other income over the weighted average life of approximately 8 years.
2 No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.
12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often be identified by the use of terminology such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:
•our expectations regarding the rate and degree of market acceptance of our antibody discovery and development engine;
•companies and technologies in our industry that compete with our business;
•our ability to manage and grow our business by introducing our antibody discovery and development engine to new partners and expanding our relationships with existing partners;
•our expectations regarding the quality of our antibody discovery and development engine and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry;
•our operating results and financial performance;
•our partners’ ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in the expected timelines or at all;
•our ability to provide our partners with a full solution from target identification to investigational new drug, or Investigational New Drug ("IND"), application submission;
•our partners’ ability to develop and commercialize a molecule discovered by us, on a timely basis or at all;
•our expectations regarding the completion of our good manufacturing practices, or GMP, facility and our manufacturing capabilities;
•our ability to establish and maintain intellectual property protection for our technologies and workflows and avoid or defend against claims of patent infringement;
•our ability to attract, hire and retain key personnel and to manage our personnel growth effectively;
•our ability to obtain additional financing in future offerings;
•the volatility of the trading price of our common shares;
•business disruptions affecting our operations and the development of our antibody discovery and development engine;
•our ability to avoid material weaknesses or significant deficiencies in our internal control over financial reporting in the future;
•our expectations regarding our Passive Foreign Investment Company, or PFIC, status for our taxable year ended December 31, 2024, or any future taxable year;
•our expectations regarding the use of our cash resources;
•our expectations about market trends; and
•our ability to predict and adapt to government regulation.
We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements. We have included important
13

factors in the cautionary statements included in this Quarterly Report, particularly in “Summary of the Material and Other Risks Associated with Our Business” above and “Risk Factors” below, that we believe could cause actual results or events to differ materially from our forward-looking statements. We operate in a competitive and rapidly changing environment and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter.
Additionally, inflation generally affects us by increasing our employee-related costs and certain other expenses. Our financial condition and results of operations may also be impacted by other factors we may not be able to control, such as global supply chain disruptions, uncertain global economic conditions, global trade disputes or political instability as further discussed in the section “Risk Factors” in this Quarterly Report.
You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may differ materially from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
This Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All market data used in this Quarterly Report involves assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.
We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to “$” and “US$” are to U.S. dollars and references to “C$” and “CAD$” are to Canadian dollars.
Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to “AbCellera,” the “Company,” “we,” “us” and “our” refer to AbCellera Biologics Inc. and its consolidated subsidiaries.
Overview
We are a team of scientists, engineers, creatives, and business professionals addressing the barriers of conventional antibody drug development. We believe investments in technology will improve the quality, speed, and success of drug development and that long-term value creation begins with building a great company that can create multiple products, repeatedly and successfully. To maximize the value and impact of our work, we are advancing a pipeline of programs and strategically partnering with groups with novel science or innovative technology.
We focus on the development of antibody-based drugs and are committed to improving discovery and development. We aim to build a competitive advantage in bringing antibody therapeutics from target into clinical testing by combining expertise, technologies, and infrastructure to build an integrated engine for antibody drug discovery and development. We think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development and in scaling a company. We look for opportunities where we believe low-risk investments in building technology and operational efficiency can create a sustained competitive advantage and drive long-term value by making biologics drug development faster and more efficient.
14

We structure our agreements in a way that is designed to align our partners’ economic interests with our own. We deliberately partner with companies of all sizes to propel programs pursuing the best ideas for new antibody-based drugs to the clinic, together. We enable discovery against targets that have traditionally been intractable, and we accelerate programs against less difficult targets.
As our capabilities have grown, we are also strategically leveraging our engine to develop internal programs to address areas of high unmet medical need and to advance our pipeline of first-in-class and best-in-class medicines.
Our deals emphasize participation in the success and upside of future antibody therapeutic candidates. Our partnership agreements include near-term payments for technology access, research and intellectual property rights, and downstream payments in the form of clinical and commercial milestones, and royalties on net sales. We also participate in alternative investment opportunities including equity in our business partners and various rights for deeper involvement in moving molecules forward. Longer-term, we are eligible to receive additional payments upon satisfaction of clinical and commercial milestones, which we refer to as milestone payments, as well as royalties on sales of approved products derived from antibodies that we discover for our partners. Our partnerships generally include royalty payments (or equivalents) on net sales. For discovery agreements, these are typically in the single-digit to low-double digit range. We believe that our internal programs, if successfully out-licensed, may generate substantial upfront payments and royalty positions on net sales in the high single-digits to high teens range, in addition to clinical and commercial milestones.
We focus a substantial portion of our resources on research and development efforts towards strengthening our discovery and development engine and developing a pipeline of internal and co-development programs. We expect to continue to make significant investments in this area for the foreseeable future, over time shifting effort from engine development towards engine application. We expect to continue to incur significant expenses in connection with our ongoing activities, including as we:
•invest in research and development activities to improve our antibody discovery and development engine including investments in completing the construction of our small-scale manufacturing facility and our new headquarters through our joint ventures;
•pursue internal and co-development programs in preclinical and eventually clinical development;
•market and sell our solutions to existing and new strategic partners;
•expand and enhance operations to deliver programs, including investments in manufacturing;
•acquire businesses or technologies to support the growth of our business;
•attract, hire and retain qualified personnel; and
•continue to establish, protect and defend our intellectual property and patent portfolio, including our ongoing litigation.
To date, we have financed our operations primarily from revenue from our antibody discovery partnerships in the form of royalty revenue, government funding from grants, and from the issuance and sale of convertible preferred shares and notes, and common shares. Additionally, we have twice secured significant government co-investments in the form of non-dilutive capital to help fund research and development, including internal programs, and facility construction.
The Company has advanced two AbCellera-led programs into IND-enabling studies. The programs align with the Company's strategy of building value, both through strategic partnerships, and through internal discovery and development of potential first-in-class and best-in-class antibody therapies. We have started a cumulative total of 95 partner-initiated programs with downstream participation and have seen a cumulative total 14 molecules advanced into the clinic, as illustrated by the following chart.
15

2024-Q3 Business Metrics Chart JPEG.jpg



Financial Highlights
The following table summarizes our key operating results for the three and nine months ended September 30, 2023 and September 30, 2024. All figures are in U.S. dollars and amounts are expressed in thousands, except loss per share data:
16


Three months ended September 30,Nine Months Ended September 30,
Financial Performance2023202420232024
Revenue:
Research fees$6,413 $6,289 $26,812 $21,516 
Licensing revenue186 218 784 767 
Milestone payments– – 1,250 1,500 
Total revenue6,599 6,507 28,846 23,783 
Operating expenses:
Research and development(1)
37,917 40,969 127,036 121,183 
Other operating expenses23,57259,20172,964144,611
Total operating expenses61,489100,170200,000265,794
Loss from operations(54,890)(93,663)(171,154)(242,011)
Total other income(15,614)(31,031)(45,727)(88,445)
Net loss before income tax(39,276)(62,632)(125,427)(153,566)
Net loss$(28,610)$(51,107)$(99,248)$(128,647)
Net loss per share
Basic$(0.10)$(0.17)$(0.34)$(0.44)
Diluted$(0.10)$(0.17)$(0.34)$(0.44)
Operating expenses include stock-based compensation:
Research and development$7,796 $7,621 $23,370 $24,199 
Sales and marketing1,264 1,545 3,864 4,473 
General and administrative6,802 7,998 20,501 23,683 
Financial Position and LiquidityDecember 31, 2023September 30, 2024
Cash and cash equivalents133,320 126,640 
Marketable securities627,265 516,499 
Total cash, cash equivalents, and marketable securities760,585 643,139 
Total assets1,488,094 1,392,828 
Total shareholders' equity1,152,318 1,078,094 
(1)Exclusive of depreciation, amortization, and impairment
Key Factors Affecting Our Results of Operations and Future Performance
We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part II, Item 1A, Risk Factors.
•Engaging with strategic partners. Our potential to grow revenue, in both the near and long term, is dependent on successfully engaging with strategic partners. For existing strategic partners, we seek to expand our relationships with them to collaborate on additional programs initiated by them as well as to create a basis for potentially out-licensing some of our internal programs. Our teams are selective in determining which partners we choose to engage with, focusing on the opportunities with the strong potential to generate significant value in the long term.
•Our partners successfully developing and commercializing the antibodies that we discover. We estimate that, based on the terms of our existing contracts and estimates of historical rates of success of antibody drug development, the vast majority of the potential value for each program is represented by potential future milestone
17

payments and royalties rather than research fees. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies that we discover based on contracts with our partners. As our partners continue to advance development of the antibodies that we have discovered, we expect to start receiving additional milestone payments and royalties if any partners commence commercial sales of such antibodies.
•Rate and timing of selecting and initiating discovery projects by our partners. Once programs are secured under contract, partners must propose targets and agree on a detailed statement of work before we commence discovery research on any antibodies. The rate and timing of such selection and initiation differs from partner to partner. Research fees that we recognize under our partnerships depend on our delivery of antibodies for development by our partners and delays by our partners in selecting targets and agreeing on statements of work will impact revenue recognition.
•Successfully out-licensing drug candidates from our internal programs. We believe that our internal programs may result in drug candidates of interest to other drug developers with capabilities complimentary to our own. Where these capabilities can be expected to enhance the value of our drug candidate, we may seek to out-license. Successful out-licensing agreements could generate substantial up-front payments in addition to later milestone payments and royalties. Our financial performance may therefore be impacted by our ability to produce and out-license such drug candidates from our internal programs.
•Investing in enhancements to our discovery and development engine. Our ability to maintain and expand our partnerships is dependent on the advantages our discovery and development engine delivers to our partners and our internal programs. We intend to maintain our leading position through investments in research and development to refine and add capabilities in areas such as computation, protein engineering, immunization technologies, genetically engineered rodents and cell line selection. Specifically, we are currently completing our investments in integrated preclinical development and antibody manufacturing. We have also successfully executed and will continue to look for strategic technology acquisitions to improve, broaden and deepen our capabilities and expertise in antibody discovery and development, or those that offer opportunities to expand our business into adjacent therapeutic modalities. We intend to continue to devote resources to continue to improve our discovery differentiation which will impact our financial performance.
•Pursuing drug discovery and development opportunities internally. As the capabilities of our discovery and development engine have matured we are increasingly in a position to pursue attractive, well-validated targets ourselves, e.g. in the GPCR, ion channel, and TCE spaces. Such programs have the potential to yield first-in-class drug candidates in indications with substantial unmet medical need which we would wholly own. We plan on investing significant resources in the preclinical and, eventually, clinical development of internal programs which will impact our financial results. The investments in each program are undertaken at risk and may ultimately not yield a return.
Key Business Metrics
We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops as further described below with respect to changes in this and upcoming reports.
Cumulative MetricsSeptember 30, 2023September 30, 2024Change %
Partner-initiated program starts with downstreams849513 %
Molecules in the clinic101440 %
18

The table below outlines the details of molecules in the clinic as of September 30, 2024:
MoleculeMost advanced stagePartnerTherapy areasProgram type
Bamlanivimab (LY-CoV555)Marketed, EUA*Eli Lilly and CompanyInfectious disease – COVID-19AbCellera-initiated; partner-led
Bebtelovimab (LY-CoV1404)Marketed, EUA*Eli Lilly and CompanyInfectious disease – COVID-19AbCellera-initiated; partner-led
TAK-920/DNL919Phase 1*Denali Therapeutics Inc.Neurology - Alzheimer's DiseaseAbCellera partner-initiated discovery
UndisclosedPhase 1Teva Pharmaceutical Industries Ltd.NeuroscienceAbCellera partner-initiated discovery
ABD-147IND cleared (Fast Track- and Orphan drug- designated)Abdera TherapeuticsOncologyAbCellera partner-initiated discovery
IVX-01Clinical field studyInvetxAnimal HealthAbCellera partner-initiated discovery
UndisclosedClinical field studyInvetxAnimal HealthAbCellera partner-initiated discovery
UndisclosedClinical field studyInvetxAnimal HealthAbCellera partner-initiated discovery
AB-2100Phase 1/2Arsenal BioOncologyTrianni license
NBL-012Phase 1NovaRock Biotherapeutics Inc.Dermatology, gastrointestinal, immunologyTrianni license
NBL-015/FL-301Phase 1NovaRock Biotherapeutics Inc.OncologyTrianni license
NBL-020Phase 1NovaRock Biotherapeutics Inc.OncologyTrianni license
NBL-028Phase 1NovaRock Biotherapeutics Inc.OncologyTrianni license
UndisclosedPhase 1*UndisclosedUndisclosedTrianni license
*Expect no further progress
Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term.
Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached "open" status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.


19

Summary partnership agreements with pharmaceutical and biotechnology companies that include downstream participation from 2016 to September 30, 2024:
Partner# of Targets & DurationTherapeutic Indication or ModalityDate Announced
Eli Lilly and CompanyMulti-target, multi-yearImmunology, cardiovascular disease, and neuroscienceJuly 31, 2024
Viking Global Investors & ArrowMark PartnersMulti-target, multi-yearImmunology May 1, 2024
Biogen Inc.Single targetNeuroscienceMarch 11, 2024
Undisclosed biotechnology companyMulti-target, multi-yearUndisclosedDecember 20, 2023*
Undisclosed biotechnology companyMulti-target, multi-yearUndisclosedDecember 4, 2023*
Prelude Therapeutics Up to 5 targets, multi-yearOncologyNovember 1, 2023
Regeneron Pharmaceuticals, Inc.Up to 4 targets, multi-yearUndisclosedSeptember 20, 2023
Incyte CorporationUndisclosedOncologySeptember 13, 2023
RQ Biotechnology Ltd.Up to 3 targets, multi-yearInfectious diseaseMarch 22, 2023
AbbVie Inc.Up to 5 targets, multi-yearUndisclosedDecember 15, 2022
Rallybio CorporationUp to 5 targets, multi-yearRare metabolic disorder and undisclosedDecember 1, 2022
Atlas' stealth stage companyUp to 3 targets, multi-yearUndisclosedAugust 3, 2022
Undisclosed biotechnology companyUp to 3 targets, multi-yearUndisclosedJune 29, 2022*
Empirico Inc.2 additional targetsUndisclosedMay 3, 2022
Everest Medicines Ltd.Up to 10 targets, multi-yearOncology and undisclosedSeptember 22, 2021
Moderna, Inc.Up to 6 targets, multi-yearRNA-encoded antibodiesSeptember 15, 2021
EQRx, Inc.Multi-target, multi-yearOncology and immunology (initially)August 4, 2021
Tachyon Inc.Single targetOncologyAugust 3, 2021
Undisclosed biotechnology companyUp to 4 targets, multi-yearUndisclosedJune 30, 2021*
AngiosMulti-target, multi-yearOphthalmologyMay 6, 2021
Undisclosed biotechnology companyMulti-target, multi-yearOncologyMay 6, 2021*
Empirico Inc.5 targets, multi-yearUndisclosedApril 14, 2021
Gilead Sciences, Inc.8 targets, multi-yearUndisclosedApril 1, 2021
Abdera Therapeutics Inc.9 targets, multi-yearOncologyJanuary 14, 2021
Invetx, Inc.Multi-target, multi-yearAnimal HealthNovember 19, 2020
Kodiak Sciences Inc.Multi-target, multi-yearOphthalmologyOctober 29, 2020
IGM Biosciences, Inc.Multi-target, multi-yearOncology and immunologySeptember 24, 2020
Undisclosed Single targetBispecificJune 3, 2020*
Eli Lilly and CompanyUp to 9 targets, multi-yearCOVID-19 program and additional indicationsMay 22, 2020*
Regeneron Pharmaceuticals, Inc.4 targets, multi-yearMultiple undisclosedMarch 16, 2020*
Invetx, Inc.Multi-target, multi-yearAnimal healthFebruary 23, 2020
UndisclosedMulti-target, multi-yearCell therapySeptember 25, 2019*
Gilead Sciences, Inc.Single targetInfectious diseaseJune 13, 2019
20

Denali Therapeutics, Inc.8 targets, multi-yearNeurological diseasesFebruary 28, 2019
Novartis AGUp to 10 targets, multi-yearUndisclosedFebruary 14, 2019
Autolus Therapeutics plcSingle targetCell therapy (CAR-T)November 29, 2018
Denali Therapeutics, Inc.Single targetNeurological diseasesJune 12, 2018
Undisclosed mid-cap biopharmaceutical companyUndisclosedUndisclosedJanuary 25, 2018
Teva Pharmaceutical Industries Ltd.Single targetMembrane proteinJune 13, 2017
Pfizer Inc.Multi-target, multi-yearMembrane proteinJanuary 5, 2017
Undisclosed global biotechnology companyMulti-target, multi-yearUndisclosedNovember 4, 2016
Kodiak Sciences Inc.Single targetOphthalmologyAugust 24, 2016
Teva Pharmaceutical Industries Ltd.UndisclosedUndisclosedFebruary 2, 2016
* Effective date of agreement

Results of Operations
Comparison of the three and nine months ended September 30, 2023 and September 30, 2024:
Revenue
Three Months Ended September 30,Change Nine Months Ended September 30,Change
20232024Amount % 20232024Amount %
Revenue:
Research fees$6,413 $6,289 $(124)(2)%$26,812 $21,516 $(5,296)(20)%
Licensing revenue186 218 32 17 %784 767 (17)(2)%
Milestone payments— — —– %1,250 1,500 25020 %
Total revenue$6,599 $6,507 $(92)(1)%$28,846 $23,783 $(5,063)(18)%
Revenue decreased by $0.1 million from the three months ended September 30, 2023 compared to the three months ended September 30, 2024, and decreased $5.1 million from the nine months ended September 30, 2023 compared to the nine months ended September 30, 2024. The decrease in research fees in both periods was attributable to the timing and progress of our research and development efforts.
Operating Expenses
Research and Development
Three Months Ended September 30,Change Nine Months Ended September 30,Change
20232024Amount%20232024Amount %
Research and development37,917 40,969 3,052 8 %127,036 121,183 (5,853)(5)%
Research and development expenses increased by $3.1 million, or 8%, from the three months ended September 30, 2023 compared to the three months ended September 30, 2024. Research and development expenses reflect the continued growth in program execution, platform development, forward integration, and investment in partnered and internal programs, all of which contribute to increased capabilities and capacity of AbCellera's engine for antibody discovery and development. Of the total increase, $0.6 million is attributable to compensation-related expenses and $2.5 million is attributable to facilities, supplies and services expenditure consistent with the overall growth of the Company.
21

Research and development expenses decreased by $5.9 million, or (5)%, from the nine months ended September 30, 2023 compared to the nine months ended September 30, 2024. Research and development expenses reflect the continued growth in program execution, platform development, forward integration, and investment in partnered and internal programs, all of which contribute to increased capabilities and capacity of AbCellera's engine for antibody discovery and development. The decrease is attributable to specific one-time investments in co-development and internal programs of approximately $20.0 million made in the first quarter of 2023. The overall decrease was partially offset by an increase of $6.2 million in compensation-related expenses and a $8.1 million increase in facilities, supplies and services expenditure consistent with the overall growth of the Company.
Sales and Marketing
Three Months Ended September 30,Change Nine Months Ended September 30,Change
20232024Amount%20232024Amount %
Sales and marketing3,468 3,135 (333)(10)%11,080 9,635 (1,445)(13)%
Sales and marketing expenses decreased by $0.3 million, or (10)%, from the three months ended September 30, 2023 compared to the three months ended September 30, 2024 and decreased by $1.4 million, or (13)%, from the nine months ended September 30, 2023 compared to the nine months ended September 30, 2024. The decrease in both periods was attributable to a reduction in consulting fees and other expenses related to our business development activity.
General and Administrative
Three Months Ended September 30,Change Nine Months Ended September 30,Change
20232024Amount%20232024Amount %
General and administrative14,369 19,147 4,778 33 %45,025 56,691 11,666 26 %
General and administrative expenses increased by $4.8 million, or 33%, from the three months ended September 30, 2023 compared to the three months ended September 30, 2024. The increase was driven by a $1.2 million increase in compensation-related costs and a $3.6 million increase in legal, software, and other general administrative costs.
General and administrative expenses increased by $11.7 million, or 26%, from the nine months ended September 30, 2023 compared to the nine months ended September 30, 2024. The increase was driven by a $2.9 million increase in compensation-related costs and a $8.7 million increase in legal, software, and other general administrative costs.
Depreciation, Amortization, and Impairment
Three Months Ended September 30,Change Nine Months Ended September 30,Change
20232024Amount%20232024Amount %
Depreciation, amortization, and impairment5,735 36,919 31,184 544 %16,859 78,285 61,426 364 %
Depreciation, amortization, and impairment expenses increased by $31.2 million, or 544%, from the three months ended September 30, 2023 compared to the three months ended September 30, 2024. The increase relates primarily to a full impairment charge of the carrying value of $32.0 million (or $23.3 million, net of deferred income tax) associated with the IPR&D acquired through the 2020 acquisition of Trianni. The impairment was due to our ongoing internal program prioritization which resulted in the discontinuance of the development of the next-generation transgenic mice.
Depreciation, amortization and impairment expenses increased by $61.4 million, or 364%, from the nine months ended September 30, 2023 compared to the nine months ended September 30, 2024. In addition to the Trianni IPR&D impairment mentioned above, the remaining increase relates primarily to a full impairment charge of the carrying value of $32.0 million (or $23.7 million, net of deferred income tax) associated with the IPR&D acquired through the 2021 acquisition of TetraGenetics. The TetraGenetics impairment was a result of the Company's ongoing internal program prioritization.
22

Interest Income
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20232024Amount%20232024Amount%
Interest income(10,740)(9,603)